On Tuesday, Alector, Inc. (NASDAQ:ALEC) announced results from the Phase 3 INFRONT-3 trial evaluating latozinemab (AL001) for frontotemporal dementia caused by a progranulin gene mutation (FTD-GRN).ALEC stock is struggling to find support. Watch the momentum hereIn the 96-week study, latozinemab, developed in collaboration with GSK plc (NYSE:GSK), did not meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating plus National Alzheimer's Coordinating C ...

(Subtitles may contain inaccuracies) We're starting things off with a closer look of what looks to be still, we're in the midst of the sell off across the precious metal space. And joining us now is the global head of commodities research at Standard Chartered, Suki Cooper, joining us from New York. Suki, good morning from the Asia Pacific.It must have been an extremely busy Tuesday for you. So thank you so much for taking the time. Do you, what do you think happened.Let's start simple. What do you think ha ...

William Blair downgraded Alector, Inc. (NASDAQ:ALEC) from "Outperform" to "Market Perform" following a failed drug trial.The company's stock price has significantly declined, currently standing at $3.21, after the announcement of the trial's failure.Alector's market capitalization is approximately $324.9 million, with a trading volume of 1,393,229 shares on the NASDAQ.Alector, Inc. (NASDAQ:ALEC) is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company aims to ha ...

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday.Shares of Netflix, Inc. (NASDAQ:NFLX) fell sharply in pre-market trading as the company reported downbeat third-quarter financial results Tuesday after market close.Netflix reported third-quarter revenue of $11.51 billion, up 17.2% year-over-year. The revenue total missed a Street consensus estimate of $11.514 billion, according to data from Benzinga Pro. The company reported earnings per share of $5. ...

格隆汇10月22日｜Alector(ALEC.US)盘前暴跌近60%。葛兰素史克声明其与美国生物科技公司Alector合 作的试验性药物latozinemab未能延缓痴呆症进展，宣告又一款潜在痴呆症治疗药物研发失败。 ...

Alector称，公司未来将专注于阿尔茨海默病和帕金森病的其他试验性疗法，包括利用其专有技术实现药 物跨血脑屏障递送的相关项目。 该公司表示，截至9月底，其现金及投资约为2.911亿美元，足以支撑公司运营至2027年。 这款名为latozinemab的药物，当时正针对由颗粒体蛋白前体基因(progranulingene)突变引发的额颞叶痴 呆患者开展试验。此类基因突变会导致患者早发且严重的认知功能衰退。 这款药物源自Alector与葛兰素史克在2021年达成的一项合作协议，该协议潜在价值超过20亿美元。该试 验由Alector与合作伙伴葛兰素史克共同开展，为期96周。结果显示，以常用评估标准衡量，该药物在延 缓疾病进展方面未产生临床获益，但确实提高了患者血液中一种关键蛋白的水平。 智通财经APP获悉，英国制药公司葛兰素史克(GSK.US)声明其与美国生物科技公司Alector(ALEC.US)合 作的试验性药物latozinemab未能延缓痴呆症进展，宣告又一款潜在痴呆症治疗药物研发失败。这款药物 由Alector公司研发，针对的是一种名为"额颞叶痴呆"的痴呆症类型。宣布这一消息后，Alector美股周三 盘 ...

King of Prussia, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biotechnology company Alector announced today that the drug, latozinemab, failed to meet the criteria for safety and efficacy in a Phase 3 clinical trial. The study investigated the drug as an intervention for cases of FTD caused by a variant of the gene GRN. Three genes, GRN, MAPT, and C9orf72, cause the majority of genetic FTD—itself roughly 20% of FTD cases. “Even though this trial shows that latozinemab is not the treatment FTD-GRN families had hop ...

Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2025 131 Oyster Point Blvd. Suite 600 South San Francisco, California 94080 (Address of Principal Executive Offices) (Zip Code) Delaware 001-38792 82-2933343 (Commission File Number) (IRS Employer Identification No.) Registrant's Telephone Number, Including Area Code: (415) 231-5660 ...

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). In the 96-week, double-blind INFRONT-3 trial, latozinemab, developed in collaboration with GSK, d ...